HIV-1 proviruses and antiretroviral therapy

A study of nine patients infected with HIV-1 for more than 10 years and treated with combination antiretroviral therapy (cART) finds that some of the “defective” proviruses—proviruses with large genetic alterations or internal deletions—that were present in the cART patients were able to successfully transcribe complete HIV-RNA transcripts, suggesting that these defective but biologically active proviruses may contribute to persistent immune activation in patients with treated HIV-1 infection. - Read at PNAS.org

Article #16-09057: “Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy,” by Hiromi Imamichi et al.